This document discusses new directions for Alzheimer's disease therapy, including defining targets for symptomatic treatment, impeding neurodegenerative processes, and considering preclinical therapy. However, preclinical therapy poses several challenges, such as determining when treatment should begin, high screening costs, requiring very large clinical trial sample sizes and long follow-up periods. Outcome measures for preclinical therapy trials are also unclear, as cognitive changes may be too subtle and amyloid imaging, CSF biomarkers, and MRI imaging each have limitations.